

Michael Ohh

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1244869/michael-ohh-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

30
papers

2,290
citations

16
h-index

30
g-index

30
ext. papers

2,632
ext. citations

12.3
avg, IF

4.35
L-index

#	Paper	IF	Citations
30	D154Q Mutation does not Alter KRAS Dimerization.. <i>Journal of Molecular Biology</i> , 2021 , 434, 167392	6.5	1
29	Side population analysis in clear cell renal cell carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2021 , 585, 196-202	3.4	
28	The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors. <i>Nature Communications</i> , 2021 , 12, 6274	17.4	5
27	Hypoxia and viral infectious diseases. <i>JCI Insight</i> , 2021 , 6,	9.9	2
26	PD-1 blockade delays tumor growth by inhibiting an intrinsic SHP2/Ras/MAPK signalling in thyroid cancer cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021 , 40, 22	12.8	9
25	HIF-1 α Hydroxyprolines Modulate Oxygen-Dependent Protein Stability Via Single VHL Interface With Comparable Effect on Ubiquitination Rate. <i>Journal of Molecular Biology</i> , 2021 , 433, 167244	6.5	1
24	The long form of pVHL is artifactually modified by serine protease inhibitor AEBSF. <i>Protein Science</i> , 2020 , 29, 1843-1850	6.3	1
23	Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS-MAPK Pathway in Neuroblastoma. <i>Cancer Research</i> , 2020 , 80, 3413-3423	10.1	20
22	Nucleolar RNA polymerase II drives ribosome biogenesis. <i>Nature</i> , 2020 , 585, 298-302	50.4	50
21	A Hypoxia-Inducible HIF1-GAL3ST1-Sulfatide Axis Enhances ccRCC Immune Evasion via Increased Tumor Cell-Platelet Binding. <i>Molecular Cancer Research</i> , 2019 , 17, 2306-2317	6.6	9
20	Evolution of metazoan oxygen-sensing involved a conserved divergence of VHL affinity for HIF1 α and HIF2 α <i>Nature Communications</i> , 2019 , 10, 3293	17.4	8
19	Disturbed Flow Increases UBE2C (Ubiquitin E2 Ligase C) via Loss of miR-483-3p, Inducing Aortic Valve Calcification by the pVHL (von Hippel-Lindau Protein) and HIF-1 α (Hypoxia-Inducible Factor-1 α)Pathway in Endothelial Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019 , 39, 467-481	9.4	32
18	Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation. <i>Nature Communications</i> , 2019 , 10, 224	17.4	43
17	Consequences of VHL Loss on Global DNA Methylation. <i>Scientific Reports</i> , 2018 , 8, 3313	4.9	9
16	HIF-2 β VHL complex reveals broad genotype-phenotype correlations in HIF-2 β -driven disease. <i>Nature Communications</i> , 2018 , 9, 3359	17.4	17
15	Translational and HIF-1 α -Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides. <i>Cell Metabolism</i> , 2018 , 28, 817-832.e8	24.6	42
14	A Late G1 Lipid Checkpoint That Is Dysregulated in Clear Cell Renal Carcinoma Cells. <i>Journal of Biological Chemistry</i> , 2017 , 292, 936-944	5.4	9

13	New structural and functional insight into the regulation of Ras. <i>Seminars in Cell and Developmental Biology</i> , 2016 , 58, 70-8	7.5	16
12	Oxygen-dependent Regulation of Erythropoietin Receptor Turnover and Signaling. <i>Journal of Biological Chemistry</i> , 2016 , 291, 7357-72	5.4	24
11	Hydroxylation-Dependent Interaction of Substrates to the Von Hippel-Lindau Tumor Suppressor Protein (VHL). <i>Methods in Molecular Biology</i> , 2016 , 1458, 87-94	1.4	3
10	Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis. <i>Nature Communications</i> , 2015 , 6, 8859	17.4	112
9	Src promotes GTPase activity of Ras via tyrosine 32 phosphorylation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, E3785-94	11.5	59
8	The multifaceted von Hippel-Lindau tumour suppressor protein. <i>FEBS Letters</i> , 2014 , 588, 2704-11	3.8	72
7	DCNL1 functions as a substrate sensor and activator of cullin 2-RING ligase. <i>Molecular and Cellular Biology</i> , 2013 , 33, 1621-31	4.8	13
6	Inhibition of SRC corrects GM-CSF hypersensitivity that underlies juvenile myelomonocytic leukemia. <i>Cancer Research</i> , 2013 , 73, 2540-50	10.1	23
5	Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. <i>Nature Genetics</i> , 2010 , 42, 794-800	36.3	257
4	pVHL Δ kryptonite: E2-EPF UCP. <i>Cancer Cell</i> , 2006 , 10, 95-7	24.3	8
3	Ubiquitin pathway in VHL cancer syndrome. <i>Neoplasia</i> , 2006 , 8, 623-9	6.4	49
2	An intact NEDD8 pathway is required for Cullin-dependent ubiquitylation in mammalian cells. <i>EMBO Reports</i> , 2002 , 3, 177-82	6.5	149
1	Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. <i>Nature Cell Biology</i> , 2000 , 2, 423-7	23.4	1247